Print Page  Close Window

Corporate Profile

Paratek is developing and commercializing innovative antibacterial therapeutics based upon tetracycline chemistry. Paratek has used its expertise in microbial biology and tetracycline chemistry to create chemically diverse and biologically distinct small molecules derived from the tetracycline class of molecules. Paratek’s two lead antibacterial product candidates are omadacycline and sarecycline. Omadacycline entered Phase 3 clinical development in June 2015. Sarecycline entered Phase 3 clinical development in December 2014.

Stock Information

PRTK (Common Stock)
ExchangeNASDAQ (US Dollar)
Change (%) Stock is Up 0.20 (2.00%)
Data as of 08/17/18 4:00 p.m. ET

Latest News

FDA Advisory Committee Recommends Approval of Paratek’s Omadacycline
Paratek Pharmaceuticals Stock Trading Halted Today; FDA Advisory Committee to Review Omadacycline New Drug Applications for the Treatment of Community-Acquired Bacterial Pneumonia and Acute Bacterial Skin and Skin Structure Infections
Paratek Pharmaceuticals Reports Second Quarter 2018 Financial Results
Paratek Pharmaceuticals to Report Second Quarter 2018 Financial Results on August 2, 2018
See More >>
Data provided by Nasdaq. Minimum 15 minutes delayed.